Branded Legacy Inc. Launches New Facility for Opioid Solutions
VANCOUVER, British Columbia — BioLegacy Evaluative Group, Inc., a key subsidiary of Branded Legacy Inc. (OTC: BLEG), is thrilled to announce the opening of a cutting-edge 22,000-square-foot Good Manufacturing Practice (GMP) facility in Vancouver, Canada. This achievement signifies a crucial step forward in developing innovative, low-cost inhaled naloxone devices to tackle the pressing issue of opioid overdoses.
The newly established facility will function as BioLegacy's primary center for research, development, and manufacturing. This initiative builds upon Branded Legacy's recent acquisition of BioLegacy Evaluative Group and strategic alliances with renowned institutions, enhancing the company’s capability to produce breakthrough therapies.
CEO Amin Janmohamed expressed enthusiasm about this significant milestone, stating, "Our new facility is the foundation for BioLegacy's mission to deliver affordable, accessible overdose-reversal solutions at scale. By integrating academic partnerships with high-end infrastructure, we are set to convert scientific advancements into life-saving products." This vision demonstrates the commitment to address the ongoing crisis effectively.
Facility Highlights
- State-of-the-Art GMP Facility – Designed in line with global pharmaceutical standards to ensure scalability and sustainable value.
- Advanced ISO Class 7 & 8 Cleanrooms – Designed for superior, compliant production, conforming to strict particle limits, thereby guaranteeing exceptional quality.
- High-Containment Capabilities – Equipped to safely handle the manufacturing of potent and hazardous substances.
- Integrated Laboratory Systems – Features in-house testing and validation processes that streamline development while minimizing costs.
- Regulatory Expertise – The on-site team with extensive experience in dealing with Health Canada and FDA ensures efficient product approvals.
Dr. Kristian Thorlund, Executive Chair of BLEG, reinforced the vital role of the new facility, highlighting the importance of developing safe and effective devices amid the opioid epidemic. He stated, "To combat the challenge presented by hazardous materials, our products must not only be potent but also designed with safety in mind. The capabilities of these new facilities present an immense opportunity for scientific progress within our organization."
A virtual tour featuring Dr. Thorlund has been made available, showcasing the facility's advanced capabilities, illustrating the commitment to transparency and stakeholder engagement.
Strategic Impact
The facility will initially focus on BioLegacy's inhaled naloxone program, enhancing the company’s patented intranasal naloxone delivery device, which is pivotal for increasing accessibility and dosing precision in treating opioid overdoses. Moreover, its adaptable infrastructure is poised to support future expansions into nasal delivery technologies for vaccines and other essential treatments, which could significantly impact global health, especially in underserved areas.
About BioLegacy Evaluative Group, Inc.
BioLegacy Evaluative Group is dedicated to addressing urgent health challenges through innovative therapies and devices. With alliances at notable universities and the recent establishment of a GMP-compliant manufacturing facility, BLEG stands ready to provide scalable, cost-efficient solutions in sectors with high demands.
About Branded Legacy, Inc.
Branded Legacy, Inc. (OTC: BLEG) operates as a holdings company focused on health and wellness solutions aimed at combating addiction. Through its subsidiary, BioLegacy Evaluative Group, and partnerships with leading academic institutions, Branded Legacy leverages cutting-edge research and advanced manufacturing techniques to provide transformative healthcare solutions.
Investor Relations:
Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077
Frequently Asked Questions
What is the primary focus of Branded Legacy Inc.'s new facility?
The facility focuses on developing innovative inhaled naloxone devices designed to combat opioid overdoses.
What distinguishes BioLegacy’s new GMP facility?
It features advanced cleanroom technologies, high-containment capabilities and aims to produce compliant pharmaceutical products to global standards.
Who is leading the initiatives at BioLegacy?
CEO Amin Janmohamed and Executive Chair Dr. Kristian Thorlund are spearheading the company’s vision and operations.
How will the new facility impact opioid overdose treatment?
It will enhance the accessibility and precision of naloxone administration, ultimately saving lives during overdose situations.
What future developments are anticipated from this facility?
Future developments may include nasal delivery of vaccines and medications, addressing urgent health needs on a global scale.
